New Studies Highlight Cannabis Impacts on Sleep, Pain, and Policy Shifts in the US
New research highlights how cannabis can affect sleep patterns, pain relief, and neuroinflammation, while several US states announce significant policy changes impacting medical and retail cannabis use
Key Points
- 1A sleep study found medicinal cannabis reduced total sleep time and REM sleep compared to placebo
- 2Animal research suggests CBD may enhance oxycodone’s pain relief and reduce opioid use
- 3A clinical trial showed 70% of fibromyalgia patients using cannabis oil achieved clinically meaningful pain relief
- 4Louisiana enacted a law jailing people for smoking cannabis near schools; Kentucky expanded medical cannabis conditions
- 5Massachusetts will audit THC potency in retail cannabis products, removing mislabeled items from shelves
Recent research has revealed that medicinal cannabis can significantly alter brain activity during sleep, with reductions in both total sleep time and REM sleep compared to placebos. While many patients turn to cannabis to help with sleep issues, these findings suggest its effects are more complex than previously thought. According to Project CBD, "cannabis may affect sleep in complex ways, even when patients use it to help them fall asleep or improve sleep quality."
In the realm of pain management, new animal studies indicate that CBD could enhance the pain-relieving effects of oxycodone while also reducing opioid self-administration. This points to a promising potential for cannabinoids in opioid-sparing strategies, which could benefit those managing chronic pain. Meanwhile, a clinical trial on cannabis oil for fibromyalgia showed that 70% of participants in the treatment group experienced clinically meaningful pain relief, alongside improvements in sleep quality and overall quality of life, as reported by NORML
Emerging evidence also suggests a role for CBD in neurodegenerative disease research. Preclinical trials in mice have shown that inhaled CBD may reduce neuroinflammation associated with Alzheimer’s disease by calming overactive immune responses in the brain. Although these findings are preliminary, they highlight the growing interest in cannabinoids as potential therapies for complex neurological conditions
On the policy front, several US states are making notable moves. Louisiana Governor Jeff Landry signed a bill imposing jail time for smoking cannabis within 2,000 feet of school campuses, citing concerns over public exposure. In Kentucky, Governor Andy Beshear expanded the state’s medical cannabis program by adding 15 new qualifying conditions, including arthritis and glaucoma. The Massachusetts Cannabis Control Commission will also begin auditing THC potency in retail products, removing items from shelves if their THC levels fall outside a specified range. Americans for Safe Access released a new guide to help patients and caregivers navigate the recent federal reclassification of medical cannabis
OG Lab notes that these developments reflect the rapid evolution of cannabis science and policy in the United States. With new research and regulatory changes emerging regularly, patients and industry players alike should stay informed about the latest findings and compliance requirements
